Immune Checkpoint Inhibitors: all 7,814 studies that test it

Page 68 of 79. Open to participants first (2,629), then studies with results posted, then the rest; newest registration first within each.

• A Safety, Tolerability and Preliminary Efficacy Evaluation of CC-90011 Given in Combination With Cisplatin and Etoposide in Subjects With First Line, Extensive Stage Small Cell Lung CancerCompletedNCT03850067Phase 1
• A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid TumorsCompletedNCT03849469Phase 1
• CM082 and JS001 in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC).Status unknownNCT03848611Phase 2
• KL-A167 Injection in Recurrent or Metastatic Nasopharyngeal CarcinomaCompletedNCT03848286Phase 2
• Assess Efficacy and Safety of Durvalumab Alone or Combined With Bevacizumab in High Risk of Recurrence HCC Patients After Curative TreatmentCompletedNCT03847428Phase 3
• A Study to Evaluate Immunotherapy Combinations in Participants With Lung CancerCompletedNCT03846310Phase 1
• Targeting the Tumor Microenvironment in R/M SCCHNStatus unknownNCT03844763Phase 1/2
• Neoadjuvant Nivolumab for Oral Cancer Combined With FDG and Anti-PD-L1 PET/CT Imaging for Response PredictionStatus unknownNCT03843515Phase 1
• Tumor Associated Antigen Specific T Cells (TAA-T) With PD1 Inhibitor for LymphomaActive, not recruitingNCT03843294Phase 1
• Paclitaxel Plus Pembrolizumab vs. Paclitaxel Weekly in ER+ Luminal B Metastatic Breast CancerWithdrawnNCT03841747Phase 2
• Immunotherapy With Nivolumab in Combination With Lenvatinib for Advanced Stage Hepatocellular CarcinomaCompletedNCT03841201Phase 2
• Combine Apatinib Mesylate With PD-1 Antibody SHR-1210 for HCC With High Risk of Recurrence After Radical ResectionStatus unknownNCT03839550Phase 2
• KN046 in Patients With Advanced Non-small Cell Lung CancerTerminatedNCT03838848Phase 2
• Feasibility and Tolerance of Nivolumab Neoadjuvant Immunotherapy in High Risk HPV Driven Oropharynx CancerCompletedNCT03838263Phase 2
• NADIM II: Neo-Adjuvant ImmunotherapyActive, not recruitingNCT03838159Phase 2
• Study of an Immunotherapeutic, DPX-Survivac, in Combination With Low Dose Cyclophosphamide & Pembrolizumab, in Subjects With Selected Advanced & Recurrent Solid TumorsActive, not recruitingNCT03836352Phase 2
• AO-176 in Multiple Solid Tumor MalignanciesCompletedNCT03834948Phase 1/2
• Nivolumab in Patients With Advanced Cutaneous Squamous Cell CarcinomaStatus unknownNCT03834233Phase 2
• TSR-042 as Maintenance Therapy for Patients With High-risk Locally Advanced Cervical Cancer After Chemo-radiationActive, not recruitingNCT03833479Phase 2
• Precision Immuno-Oncology for Advanced Non-small Cell Lung Cancer Patients With PD-1 ICI ResistanceActive, not recruitingNCT03833440Phase 2
• Durvalumab With Stereotactic Body Radiation Therapy (SBRT) vs Placebo With SBRT in Early Stage Unresected Non-small Cell Lung Cancer (NSCLC) Patients/ Osimertinib Following SBRT in Patients With Early Stage Unresected NSCLC Harboring an EGFR MutationActive, not recruitingNCT03833154Phase 3
• Pembrolizumab-Epacadostat Combination to Treat Muscle-invasive Bladder UrotheLIAl canceR: PECULIAR StudyWithdrawnNCT03832673Phase 2
• NIVOLUMAB Plus IPILIMUMAB and TEMOZOLOMIDE in Microsatellite Stable, MGMT Silenced Metastatic Colorectal CancerCompletedNCT03832621Phase 2
• Study of Pembrolizumab Following Surgery in Patients With Microsatellite Instability High (MSI-H) Solid TumorsActive, not recruitingNCT03832569Early Phase 1
• A Study of Sintilimab Compared With Docetaxel or Pemetrexed as Second-line Treatment for Patients With Stage IV Nonsquamous Non-small Cell Lung Cancer After Failure With Platinum-Containing ChemotherapyStatus unknownNCT03830411Phase 2
• PD-L1 ImagiNg to prediCt Durvalumab Treatment Response in HNSCCCompletedNCT03829007Phase 1/2
• Famitinib Plus Anti-PD1 Therapy for Advanced Urinary System Tumor, Advanced Gynecological TumorsStatus unknownNCT03827837Phase 2
• Avelumab Plus 5-FU Based Chemotherapy as Adjuvant Treatment for Stage 3 MSI-High or POLE Mutant Colon CancerTerminatedNCT03827044Phase 3
• Avelumab With Axitinib in Persistent or Recurrent Cervical Cancer After Platinum-based ChemotherapyCompletedNCT03826589Not applicable
• A Study on Safety and Efficacy of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule in Patients With Advanced Biliary Adenocarcinoma/Hepatocellular CarcinomaStatus unknownNCT03825705Phase 1/2
• Nivolumab in Combination With 5-azacytidine in Childhood Relapsed/Refractory AMLStatus unknownNCT03825367Phase 1/2
• hARnessing CAbozantinib and Durvalumab Immuno-oncology Association: ARCADIA Study"Status unknownNCT03824691Phase 2
• An Open-label, Randomized, Parallel, Non Comparative, Phase II Trial of Nivolumab Plus Ipilimumab Versus Platinum-based Chemotherapy Plus Nivolumab in Chemonaive Metastatic or Recurrent Squamous-Cell Lung Cancer (SqLC)Status unknownNCT03823625Phase 2
• Study to Determine the Safety, Tolerability, Pharmacokinetics and Recommended Phase 2 Dose (RP2D) of Livmoniplimab (ABBV-151) as a Single Agent and in Combination With Budigalimab (ABBV-181) in Participants With Locally Advanced or Metastatic Solid TumorsActive, not recruitingNCT03821935Phase 1
• Safety, Tolerability, Pharmacokinetics and Efficacy of SCT-I10A in Patients With Advanced Solid Tumors or LymphomaStatus unknownNCT03821363Phase 1
• Sintilimab in Combination With Chidamide in Refractory and Relapsed ENKTCLCompletedNCT03820596Phase 1/2
• A Study of Novel Anti-cancer Agents in Patients With Previously Untreated NSCLCActive, not recruitingNCT03819465Phase 1
• Combination of Targeted and Immunotherapy for Advanced Biliary Tract and Esophagogastric Gastric CancerWithdrawnNCT03818997Phase 2
• Proton Based Cardiac Sparing Accelerated Fractionated RadioTherapy in Unresectable NSCLCTerminatedNCT03818776Early Phase 1
• Evaluate the Clinical Benefit of a Post-operative Treatment Associating Radiotherapy + Nivolumab + Ipilimumab Versus Radiotherapy + Capecitabine for Triple Negative Breast Cancer Patients With Residual DiseaseActive, not recruitingNCT03818685Phase 2
• A Study to Assess the Effects of Multiple Study Drug Regimens in Subjects With Newly Diagnosed Locally Advanced Head and Neck Squamous Cell CarcinomaTerminatedNCT03818542Phase 1
• Atezolizumab and Bevacizumab in Patients With Recurrent or Metastatic Squamous-cell Carcinoma of the Head and NeckCompletedNCT03818061Phase 2
• Sequential TACE and SBRT Followed by ImmunoTherapy for Downstaging HCC for HepatectomyCompletedNCT03817736Phase 2
• A Phase II Study of SHR-1210 vs Placebo as Consolidation Chemotherapy After Radical Concurrent Chemoradiotherapy in Locally Advanced ESCCStatus unknownNCT03817658Phase 2
• SHR-1210 in Combination With Apatinib in Patients With Metastatic, Persistent, or Recurrent Cervical CancerCompletedNCT03816553Phase 2
• Testing the Combination of Anetumab Ravtansine With Either Nivolumab, Nivolumab and Ipilimumab, or Gemcitabine and Nivolumab in Advanced Pancreatic CancerActive, not recruitingNCT03816358Phase 1
• Avelumab Program Rollover StudyActive, not recruitingNCT03815643Phase 3
• Phase II Trial of Pembrolizumab in Recurrent or Metastatic HNSCCActive, not recruitingNCT03813836Phase 2
• A Clinical Study To Evaluate Camrelizumab (SHR-1210) Plus Capecitabine and Oxaliplatin Followed by Sequential Treatment With Camrelizumab Plus Apatinib Mesylate in Advanced or Metastatic Gastric Cancer (GC) or Gastroesophageal Junction Cancer (GEJ) Without Prior Systemic TherapyCompletedNCT03813784Phase 3
• Bevacizumab and Pembrolizumab Combination in Platinum-resistant Recurrent/Metastatic NPCActive, not recruitingNCT03813394Phase 1/2
• Epigenetic Modulation of the immunE Response in GastrointEstinal Cancers (EMERGE)Status unknownNCT03812796Phase 2
• Nivolumab and Yttrium-90 in Treating Patients With Liver Cancer Undergoing Surgical ResectionTerminatedNCT03812562Early Phase 1
• Toripalimab as Monotherapy for Patients With Small Cell Carcinoma of Esophagus Who Failed ChemotherapyStatus unknownNCT03811379Phase 2
• Testing Immunotherapy Versus Observation in Patients With HPV Throat CancerActive, not recruitingNCT03811015Phase 3
• A Study of CS1003 in Subjects With Advanced Solid Tumors or LymphomasCompletedNCT03809767Phase 1
• Study of INBRX-105 and INBRX-105 With Pembrolizumab in Patients With Solid Tumors Including Head and Neck CancerTerminatedNCT03809624Phase 1
• A Study in Recurrent or Metastatic Cervical Cancer Patients With PD-L1 PositiveStatus unknownNCT03808857Phase 2
• Nivolumab After Cyclophosphamide and Doxorubicin Induction Therapy in NSCLC With PD-L1<10%Status unknownNCT03808480Phase 2
• Nivolumab Based Immunotherapy for Treatment of High Grade Cervical DysplasiaWithdrawnNCT03808168Phase 2
• Stereotactic Radiation and Nivolumab in the Management of Metastatic Breast Cancer Brain MetastasesCompletedNCT03807765Phase 1
• FUSCC Refractory TNBC Umbrella (FUTURE)Status unknownNCT03805399Phase 1/2
• Identification and Treatment Of Micrometastatic Disease in Stage III Colon CancerActive, not recruitingNCT03803553Phase 3
• HAIC Plus Lenvatinib and PD-1 Antibody Versus HAIC Plus Lenvatinib for Advanced HCCWithdrawnNCT03803254Phase 2
• Immunotherapy Combined With Y-90 and SBRT for Colorectal Liver MetastasesWithdrawnNCT03802747Phase 1
• Combination of Talimogene Laherparepvec With Atezolizumab in Early Breast CancerCompletedNCT03802604Early Phase 1
• A Study of CS1001 in Subjects With Gastric Adenocarcinoma or Gastro-Esophageal Junction AdenocarcinomaCompletedNCT03802591Phase 3
• Sintilimab ± IBI305 Plus Chemotherapy (Pemetrexed + Cisplatin) for EGFRm + Locally Advanced or Metastasis Non-Squamous NSCLC Patients After EGFR-TKI Treatment FailureCompletedNCT03802240Phase 3
• Trial to Evaluate Safety and Efficacy of Vinorelbine With Metronomic Administration in Combination With Atezolizumab as Second-line Treatment for Patients With Stage IV Non-small Cell Lung CancerCompletedNCT03801304Phase 2
• The Ave-CRT Study for Newly Diagnosed Metastatic Esophageal Squamous Cell CarcinomaStatus unknownNCT03800953Phase 2
• A Phase II Study to Evaluate the Safety and Efficacy of TQB2450 Injection in Relapsed or Refractory Classical Hodgkin's LymphomaStatus unknownNCT03800706Phase 2
• A Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients With Resectable Non-small Cell Lung CancerActive, not recruitingNCT03800134Phase 3
• Atezolizumab Plus One-year BCG Bladder Instillation in BCG-naive High-risk Non-muscle Invasive Bladder Cancer PatientsActive, not recruitingNCT03799835Phase 3
• Safety,Tolerability,and Efficacy of VCN-01 With Durvalumab in R/M Head and Neck Squamous Cell CarcinomaStatus unknownNCT03799744Phase 1
• Nivolumab and Pomalidomide in Treating Patients With Relapsed or Refractory Central Nervous System Diffuse Large B Cell Lymphoma or Primary Vitreoretinal Diffuse Large B Cell LymphomaCompletedNCT03798314Phase 1
• A Study of Pazopanib and Durvalumab for Metastatic Soft Tissue SarcomaCompletedNCT03798106Phase 2
• A Proof of Concept, Window Trial of the IMmunological Effects of AveLumab and Aspirin in Triple-Negative Breast CancerWithdrawnNCT03794596Phase 2
• A Trial of SHR-1210 in Combination With Apatinib in Patients With Unresectable HCCStatus unknownNCT03793725Phase 2
• Testing the Timing of Pembrolizumab Alone or With Chemotherapy as First Line Treatment and Maintenance in Non-small Cell Lung CancerActive, not recruitingNCT03793179Phase 3
• Phase I-II Study of Intratumoral Urelumab Combined With Nivolumab in Patients With Solid TumorsStatus unknownNCT03792724Phase 1/2
• Lenvatinib Plus PD-1 Antibody vs TACE for Intermediate-stage HCC Beyond Up-to-seven CriteriaWithdrawnNCT03791918Phase 3
• Study of a PD-1 Inhibitor (JTX-4014) in Subjects With Solid Tumor MalignanciesCompletedNCT03790488Phase 1
• A Study of CS1001 in Subjects With Stage IV Non-Small Cell Lung CancerCompletedNCT03789604Phase 3
• Vaccination With Flt3L, Radiation, and Poly-ICLCCompletedNCT03789097Phase 1/2
• A Study of Atezolizumab in Unresectable or Advaced Malignant Pleural MesotheliomaWithdrawnNCT03786419Phase 2
• Study to Evaluate Efficacy of PDR001 in Patients With Squamous Cell Carcinoma of the EsophagusStatus unknownNCT03785496Phase 2
• Phase I/II Study of Perioperative Chemotherapy Plus Immunotherapy Followed by Surgery in Localized Esophageal and Gastroesophageal AdenocarcinomaActive, not recruitingNCT03784326Phase 2
• Durvalumab With or Without Tremelimumab in Resectable Locally Advanced Squamous Cell Carcinoma of the Oral CavityActive, not recruitingNCT03784066Phase 1/2
• Nivolumab, Ipilimumab and OTSGC-A24 Therapeutic Peptide Vaccine in Gastric Cancer - a Combination Immunotherapy Phase Ib Study.Status unknownNCT03784040Phase 1
• TACE Plus PD-1 Antibody vs TACE Alone for Unresectable HCCWithdrawnNCT03782831Phase 2
• Phase 1 Study in Patients With Advanced and/or Refractory Solid Malignancies to Evaluate the Safety of ATOR-1015CompletedNCT03782467Phase 1
• HAIC Plus PD-1 Antibody vs HAIC Plus Sorafenib for Advanced HCCWithdrawnNCT03780634Phase 2
• Lenvatinib Plus PD-1 Antibody for Unresectable ICCSuspendedNCT03779100Phase 2
• A Global Study to Evaluate Transarterial Chemoembolization (TACE) in Combination With Durvalumab and Bevacizumab Therapy in Patients With Locoregional Hepatocellular CarcinomaActive, not recruitingNCT03778957Phase 3
• Study of Cosibelimab in Subjects With Relapsed or Refractory LymphomaTerminatedNCT03778073Phase 1
• Association of Radiochemotherapy and Immunotherapy for the Treatment of Unresectable Oesophageal caNcerCompletedNCT03777813Phase 2
• Phase II Study of SHR-1210(Anti-PD-1 Antibody) Combination With Apatinib Versus Pemetrexed and Carboplatin in Subjects With KRAS Mutant Stage IV Non-squamous Non-small Cell Lung CancerTerminatedNCT03777124Phase 2
• Nivolumab, Ipilimumab and Chemoradiation in Treating Patients With Resectable Gastric CancerActive, not recruitingNCT03776487Phase 2
• Lenvatinib Plus PD-1 Antibody for Intermediate-stage HCC Beyond Up-to-seven CriteriaWithdrawnNCT03775707Phase 2
• Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder CancerActive, not recruitingNCT03775265Phase 3
• Maintenance Avelumab Immunotherapy in Patients With Locally Advanced or Metastatic Squamous Cell Penile CarcinomaStatus unknownNCT03774901Phase 2

← Immune Checkpoint Inhibitors overview